Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 18 other studies
878people with arrhythmia, in this paper
The trial randomly assignedassigned by chance
SGLT2 inhibitors
control (implied)
Probably reduced HF hospitalization−31%
No clear effect on atrial fibrillation−17%
No clear effect on cardiovascular deaths−18%
randomisedthe abstract, start to end
… on atrial fibrillation odds ratio (OR) = 0.83, 95% confidence interval (CI): 0.68-1.01, prediction interval (PI): 0.57-1.19; on HF hospitalization OR = 0.69, 95% CI: 0.60-0.78, PI: 0.60-0.78; on cardiovascular death OR = 0.82, 95% CI: 0.58-1.15, PI: 0.42-1.60; and on major adverse cardiovascular events OR = 0.90, 95% CI: 0.77-1.06, PI: …
← favours treatmentfavours comparator →
could be chanceAtrial fibrillationSGLT2 inhibitors vs control (implied)
OR 0.830.68–1.01
HF hospitalizationSGLT2 inhibitors vs control (implied)
OR 0.690.60–0.78
Cardiovascular deathSGLT2 inhibitors vs control (implied)
OR 0.820.58–1.15
Major adverse cardiovascular eventsSGLT2 inhibitors vs control (implied)
OR 0.900.77–1.06
SGLT2 inhibitorsCardiovascular eventsAdverse events & safety
SGLT2 inhibitors × cardiovascular eventshelps?mixed
unlikelylikely
0.50not counted
SGLT2 inhibitors × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
← favours comparatorfavours treatment →
1 / 6